Similar Articles
1081 Mechanisms of pyruvate kinase M2 isoform inhibits cell motility in hepatocellular carcinoma cells
1082 Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients
1083 Biological features and biomarkers in hepatocellular carcinoma
1084 Optimal combination of antiangiogenic therapy for hepatocellular carcinoma
1085 Transcatheter arterial infusion for advanced hepatocellular carcinoma: Who are candidates?
1086 Current and future treatments for hepatocellular carcinoma
1087 Overexpression of chaperonin containing TCP1, subunit 3 predicts poor prognosis in hepatocellular carcinoma
1088 Current management of patients with hepatocellular carcinoma
1089 Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy
1090 Perspective of laparoscopic liver resection for hepatocellular carcinoma
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA